Suchergebnisse - "Breccia, Massimo"

PubPharm (40)

1

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia : A study from the Registro Italiano LMC and Campus CML

enthalten in: Cancer | 2023

von Tiribelli, M. | Latagliata, R. | Breccia, M. | +38

2

The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines : Findings from a Real-World Analysis in Italy

enthalten in: Advances in therapy | 2023

von Breccia, M. | Chiodi, F. | Nardozza, A. | +8

3

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

enthalten in: Journal of hematology & oncology | 2022

von García-Gutiérrez, V. | Breccia, M. | Jabbour, E. | +2

4

Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials : a real-life cohort observational study

enthalten in: Acta oncologica (Stockholm, Sweden) | 2021

von Stagno, F. | Breccia, M. | Annunziata, M. | +24

5

Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study

enthalten in: Leukemia | 2021

von Breccia, M. | Pregno, P. | Castagnetti, F. | +13

6

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

enthalten in: Annals of hematology | 2021

von Scalzulli, E. | Caocci, G. | Efficace, F. | +12

7

First-line dasatinib discontinuation in chronic myeloid leukaemia : another step towards an "operational cure"

enthalten in: The Lancet. Haematology | 2020

von Breccia, M. | Foà, R.

8

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

enthalten in: International journal of cardiology | 2020

von Caocci, G. | Mulas, O. | Annunziata, M. | +31

9

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

enthalten in: Leukemia | 2020

von Efficace, F. | Stagno, F. | Iurlo, A. | +20

10

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

enthalten in: Annals of hematology | 2019

von Caocci, G. | Mulas, O. | Abruzzese, E. | +20